X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (39) 39
index medicus (37) 37
humans (30) 30
united states (17) 17
united states food and drug administration (15) 15
cancer (13) 13
clinical trials (10) 10
drug approval (10) 10
antineoplastic agents - therapeutic use (9) 9
treatment outcome (9) 9
female (8) 8
male (8) 8
quality of life (8) 8
clinical trials as topic (6) 6
patients (6) 6
abridged index medicus (5) 5
aged (5) 5
animals (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
clinical trials as topic - methods (5) 5
disease-free survival (5) 5
neoplasms - drug therapy (5) 5
patient reported outcome measures (5) 5
patient-reported outcomes (5) 5
research design (5) 5
chemotherapy (4) 4
clinical-trials (4) 4
docetaxel (4) 4
fda approval (4) 4
hematology, oncology and palliative medicine (4) 4
pain (4) 4
prostate cancer (4) 4
quality-of-life (4) 4
regulatory agencies (4) 4
safety (4) 4
survival (4) 4
therapy (4) 4
adult (3) 3
adverse events (3) 3
aged, 80 and over (3) 3
bevacizumab (3) 3
breast neoplasms - drug therapy (3) 3
breast neoplasms - pathology (3) 3
care and treatment (3) 3
cell lung-cancer (3) 3
decision making (3) 3
diarrhea (3) 3
fda (3) 3
immunotherapy (3) 3
lung neoplasms - drug therapy (3) 3
medical research (3) 3
middle aged (3) 3
prostatic neoplasms, castration-resistant - pathology (3) 3
randomization (3) 3
research (3) 3
taxoids - administration & dosage (3) 3
trial (3) 3
urology (3) 3
analysis (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
appetite (2) 2
article (2) 2
bone neoplasms - secondary (2) 2
breast (2) 2
breast-cancer (2) 2
canada (2) 2
cancer clinical-trials (2) 2
cancer therapies (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
care (2) 2
clear cell-type renal cell carcinoma (2) 2
clinical trial (2) 2
confidence intervals (2) 2
cooperative behavior (2) 2
development and progression (2) 2
drug approval - legislation & jurisprudence (2) 2
drug development (2) 2
drug resistance (2) 2
drug-related side effects and adverse reactions - pathology (2) 2
drugs (2) 2
efficacy (2) 2
elderly-patients (2) 2
end-points (2) 2
endpoint determination (2) 2
erlotinib (2) 2
europe (2) 2
fatigue (2) 2
guidance (2) 2
health aspects (2) 2
health care sciences & services (2) 2
health-related quality of life (2) 2
homologous recombination (2) 2
interdisciplinary communication (2) 2
kaplan-meier estimate (2) 2
kidney - enzymology (2) 2
leukemia (2) 2
lung cancer (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JNCI: Journal of the National Cancer Institute, ISSN 0027-8874, 05/2019, Volume 111, Issue 5, pp. 459 - 464
Abstract Background Patient-reported outcomes (PROs) are commonly included in submissions to the United States Food and Drug Administration (FDA). Open-label... 
Journal Article
Seminars in Oncology, ISSN 0093-7754, 02/2016, Volume 43, Issue 1, pp. 2 - 3
Basic research in cancer biology, genetics and immunology has resulted in improved insights into mechanisms that drive tumor initiation and growth. This... 
Endpoints | Clinical trials | Regulation | TRIALS | ONCOLOGY | Humans | Immunotherapy | Drug Discovery - trends | Endpoint Determination | Patient Outcome Assessment | Molecular Targeted Therapy | Forecasting | Neoplasms - drug therapy
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 12/2018
On December 20, 2017, the FDA granted regular approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients... 
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 12/2018, Volume 13, Issue 12, pp. 1815 - 1817
Journal Article
Clinical Trials, ISSN 1740-7745, 6/2019, Volume 16, Issue 3, pp. 322 - 326
Background Patient-reported outcome measures can be used to capture the patient’s experience with disease and treatment. Immunotherapy agents including the... 
Therapy | Regulatory agencies | PD-1 protein | Lung | Medical services | Clinical trials | Pruritus | Pain | Immunotherapy | Risk assessment | Head and neck | Signs and symptoms | Medical treatment | Mortality | Melanoma | Diarrhea | Patients | Fever | Cough | Quality of life | Side effects | Inhibitors | PD-L1 protein | Ligands | Death | Clear cell-type renal cell carcinoma | Apoptosis
Journal Article
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2016, Volume 22, Issue 20, pp. 4968 - 4972
On February 19, 2016, the FDA approved palbociclib (Ibrance, Pfizer) for use in combination with fulvestrant (Faslodex, AstraZeneca) for the treatment of women... 
Journal Article
Journal Article
Pharmacoepidemiology and drug safety, 08/2019
Cancer trials are often open-label and include patient-reported outcomes (PROs). Previous work has demonstrated that patients may complete PRO assessments less... 
Index Medicus
Journal Article
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, ISSN 1176-6336, 2010, Volume 6, pp. 579 - 583
A single nucleotide polymorphism (SNP) in CYP2C8 (rs1934951), was previously identified in a genome-wide association study as a risk factor for the development... 
CYP2C8 | bisphosphonates | ONJ | polymorphism | HEALTH CARE SCIENCES & SERVICES | Health risk assessment | Prostate cancer | Metastasis | Original Research
Journal Article
Journal Article
Clinical trials (London, England), 03/2019, p. 1740774519836991
Patient-reported outcome measures can be used to capture the patient's experience with disease and treatment. Immunotherapy agents including the... 
Journal Article
The Oncologist, ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 762 - 767
With the Breakthrough Therapy Designation program adding to the tools that the U.S. Food and Drug Administration (FDA) has for expediting drug development, the... 
CELL LUNG-CANCER | 1ST-LINE TREATMENT | FDA APPROVAL | ONCOLOGY | RESPONSE RATE | CRIZOTINIB | IMPROVED SURVIVAL | LEUKEMIA | OUTCOMES | CHEMOTHERAPY | ERLOTINIB | Medical Oncology | Drug Approval - methods | Humans | Index Medicus | Commentaries
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.